Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-024-09135-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Loredana Amoroso und 9 weiteren Autor:innen. Beteiligte Einrichtung: UOC Oncology, IRCCS Istituto G. Gaslini, UOC Oncology, Genova, Italy. loredanaamoroso@gaslini.org. Hauptthemen laut MEDLINE: Neuroblastoma, Antibodies, Monoclonal, Immunotherapy, Antineoplastic Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: EUSA Pharma, Recordati Rare Diseases.
Abstract (Originalsprache)
PURPOSE: Patients with high-risk neuroblastoma (HR NB) frequently present with metastases in the bone marrow and bone. Approximately 15% of these patients are refractory to induction therapy, and 50% relapse. Dinutuximab beta is an anti-GD2 monoclonal antibody approved in Europe for maintenance therapy of pediatric patients with HR NB. Immunotherapy with anti-GD2 antibodies improves the survival of children with HR NB and relapsed or refractory disease. It is associated with adverse events, such as pain, fever, allergic reactions, capillary leak syndrome, and diarrhea. This manuscript aims to propose a practical guide in support and prevention treatment of adverse events. METHODS: MEDLINE was searched using the terms "GD2," "ch14.18/CHO," "anti-GD2 antibody," "dinutuximab beta," and "neuroblastoma." The experts reappraised available evidence discussing different clinical Italian experiences. RESULTS: Neuropathic pain is the main toxicity associated with dinutuximab beta and can be prevented with analgesics, including intravenous opioids and gabapentin by mouth. The intensity of the supportive treatment decreases from course to course. CONCLUSION: In the experience of the authors, adverse events associated with dinutuximab beta may be prevented and managed in experienced centers. The supportive therapy may be reduced after the first cycle to improve the quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOC Oncology, IRCCS Istituto G. Gaslini, UOC Oncology, Genova, Italy. loredanaamoroso@gaslini.org.
- Pediatric Oncology and Oncohematology Unit, Department of Maternal Infantile and Urological Sciences, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy. loredanaamoroso@gaslini.org.
- Pediatric Oncology Department, Regina Margherita Children's HospitalA.O.U. Città Della Salute E Della Scienza Di Torino, Turin, Italy.
- Centro Di Eccellenza Di Oncologia Ed Ematologia Pediatrica, SOC "Oncologia, Ematologia, TCSE E Terapia Genica" IRCCS, AUO A. Meyer, Florence, Italy.
- UOC Oncology, IRCCS Istituto G. Gaslini, UOC Oncology, Genova, Italy.
- Department of Clinical and Experimental Medicine Unit of Pediatric Hematology and Oncology, Policlinico Hospital University of Catania, Catania, Italy.
Förderung
- EUSA Pharma
- Recordati Rare Diseases
Zitieren
APA
Amoroso, L., Fagioli, F., Tondo, A., Conte, M., Badino, C., Di Cataldo, A., Viscardi, E., De Leonardis, F., De Ioris, M. A., & Luksch, R. (2025). Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-09135-5
Vancouver
Amoroso L, Fagioli F, Tondo A, Conte M, Badino C, Di Cataldo A, et al. Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review. Supportive Care in Cancer. 2025. doi:10.1007/s00520-024-09135-5
BibTeX
@article{Amoroso2025,
author = {Amoroso, Loredana and Fagioli, Franca and Tondo, Annalisa and Conte, Massimo and Badino, Clara and Di Cataldo, Andrea and Viscardi, Elisabetta and De Leonardis, Francesco and De Ioris, Maria Antonietta and Luksch, Roberto},
title = {Strategies to manage the adverse effects of immunotherapy with dinutuximab beta in neuroblastoma: an Italian experience and literature review},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-024-09135-5}
}
EUVIMED